The present disclosure provides methods for determining the effectiveness of a cancer therapy, as well as methods for increasing the effectiveness of that therapy and determining a prognosis for a patient receiving that therapy.

The invention relates to methods for phenotypic antimicrobial susceptibility profiling of unidentified pathogens directly from patient samples and uses thereof, including providing timely important information for evidence-based management of patients with infections from unidentified pathogens.

The present invention relates to biomarkers which comprise one or more genomic sequence(s) comprising epigenetic modification and their use in a method for predicting resistance to cancer treatment, in particular for patient stratification.

This disclosure provides immunogenic compositions and methods of producing immunogenic compositions sufficient to produce an antigen-specific immune response against variant influenza virus strains. Also provided herein are methods of identifying drug-resistant influenza virus strains.

The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.

A method of rapidly evaluating the susceptibility of a strain of bacteria to a cell wall synthesis inhibiting antibiotic based on an assessment of cell enlargement in response to doses of the cell wall synthesis inhibiting antibiotic which are correlated to breakpoints of bacterial susceptibility.

Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog (Rana (Lithobates) catesbeiana) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.

Disclosed are compositions, methods and systems for detecting MRSA, for example MRSA nasal colonization. In certain embodiments, the methods use bacteriophage-based amplification of the signal in detection of bacteria and other microorganisms to detect MRSA. The methods for detecting MRSA may include preparing an assay comprising a selective agent and a cocktail comprising at least two different types of recombinant bacteriophages, incubating the sample in the assay, capturing an indicator protein product, and detecting an indicator protein product produced by the recombinant bacteriophage, wherein positive detection of the indicator protein product indicates that MRSA is present in the sample.

The invention relates to a method for the preparation of living, microbial samples and microorganisms for subsequent mass spectrometric measurement and evaluation. Findings which can be derived from such a measurement can particularly serve the faster identification of microorganisms in the microbial sample according to species/subspecies and/or the fast determination of resistance/sensitivity of the microorganisms to antimicrobial substances and/or the further characterization of microorganisms, for example in respect of pathogenicity, virulence and metabolism. According to a preferred embodiment of the invention, the preparation particularly takes place directly on a mass spectrometric sample support.

The present invention relates to methods of prognosing and monitoring cancer using circulating cells and/or extracellular vesicles as indicators of the progression of plasma cell neoplasms in patients.